A Comprehensive Prognostic and Immunological Implications of Gremlin 1 in Lung Adenocarcinoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Mar 11

PMID 40066442

Authors

Hongyan Li

Yang Zhou

Jiaqing Xiao

Fang Liu

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) is a prevalent form of lung cancer globally, known for its high invasiveness, metastatic potential, and notable heterogeneity, particularly in its response to immunotherapy. Gremlin 1 (GREM1) is implicated in tumor progression and poor prognosis in multiple cancers. However, GREM1's specific role in LUAD remains unclear. This study systematically examines GREM1 expression in LUAD and its association with tumor progression, immune microenvironment, and prognosis.

Methods: Gene expression data from the TCGA and GSE31210 databases were analyzed using Weighted Gene Co-expression Network Analysis (WGCNA), GO and KEGG enrichment analyses. The prognostic value of GREM1 was evaluated through survival analysis, Cox regression, and Kaplan-Meier curves. Additionally, immune microenvironment analysis was conducted to explore the relationship between GREM1 and immune cell infiltration. experiments, including Western blot and assays for cell proliferation, migration, and invasion, were performed to confirm the specific role of GREM1 in LUAD cells.

Results: GREM1 was significantly upregulated in tumor tissues and correlated with poor prognosis. Moreover, GREM1 was significantly associated with immune cell infiltration and immunotherapy response within the immune microenvironment. experiments confirmed that GREM1 overexpression significantly promoted LUAD cell proliferation, migration, and epithelial-mesenchymal transition (EMT), whereas GREM1 knockdown suppressed these functions.

Conclusions: A comprehensive analysis indicates that GREM1 is crucial in LUAD progression, with its overexpression predicting poor prognosis. GREM1 could be a potential therapeutic target for LUAD, providing insights for personalized therapy optimization.

References

Koli K, Sutinen E, Ronty M, Rantakari P, Fortino V, Pulkkinen V . Gremlin-1 Overexpression in Mouse Lung Reduces Silica-Induced Lymphocyte Recruitment - A Link to Idiopathic Pulmonary Fibrosis through Negative Correlation with CXCL10 Chemokine. PLoS One. 2016; 11(7):e0159010. PMC: 4948891. DOI: 10.1371/journal.pone.0159010. View

Wu Z, Liu R, Miao X, Li D, Zou Q, Yuan Y . Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma. J Cancer. 2020; 11(1):199-207. PMC: 6930392. DOI: 10.7150/jca.36886. View

Sung N, Kim N, Surh Y, Park S . Gremlin-1 Promotes Metastasis of Breast Cancer Cells by Activating STAT3-MMP13 Signaling Pathway. Int J Mol Sci. 2020; 21(23). PMC: 7730512. DOI: 10.3390/ijms21239227. View

Gentles A, Hui A, Feng W, Azizi A, Nair R, Bouchard G . A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biol. 2020; 21(1):107. PMC: 7206807. DOI: 10.1186/s13059-020-02019-x. View

Gao Z, Houthuijzen J, Ten Dijke P, Brazil D . GREM1 signaling in cancer: tumor promotor and suppressor?. J Cell Commun Signal. 2023; 17(4):1517-1526. PMC: 10713512. DOI: 10.1007/s12079-023-00777-4. View

Feng S, Xu Y, Dai Z, Yin H, Zhang K, Shen Y . Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer. Front Immunol. 2022; 13:951582. PMC: 9304893. DOI: 10.3389/fimmu.2022.951582. View

Kim N, Sung N, Youn H, Park S . Gremlin-1 activates Akt/STAT3 signaling, which increases the glycolysis rate in breast cancer cells. Biochem Biophys Res Commun. 2020; 533(4):1378-1384. DOI: 10.1016/j.bbrc.2020.10.025. View

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

Kan J, Fu B, Zhou R, Zhou D, Huang Y, Zhao H . He-Chan Pian inhibits the metastasis of non-small cell lung cancer via the miR-205-5p-mediated regulation of the GREM1/Rap1 signaling pathway. Phytomedicine. 2021; 94:153821. DOI: 10.1016/j.phymed.2021.153821. View

10.

Yu Y, Cheng L, Yan B, Zhou C, Qian W, Xiao Y . Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Int J Oncol. 2018; 53(6):2445-2457. PMC: 6203161. DOI: 10.3892/ijo.2018.4573. View

11.

Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M . Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6):341-352. PMC: 7250738. DOI: 10.1038/s41580-020-0237-9. View

12.

Zhu D, Zhao D, Wang N, Cai F, Jiang M, Zheng Z . Current status and prospects of GREM1 research in cancer (Review). Mol Clin Oncol. 2023; 19(3):69. PMC: 10442762. DOI: 10.3892/mco.2023.2665. View

13.

Lan L, Evan T, Li H, Hussain A, Josue Ruiz E, Zaw Thin M . GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature. 2022; 607(7917):163-168. DOI: 10.1038/s41586-022-04888-7. View

14.

Namkoong H, Shin S, Kim H, Ha S, Cho G, Hur S . The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer. 2006; 6:74. PMC: 1459871. DOI: 10.1186/1471-2407-6-74. View

15.

Mason M, Lapuente-Santana O, Halkola A, Wang W, Mall R, Xiao X . A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J Transl Med. 2024; 22(1):190. PMC: 10880244. DOI: 10.1186/s12967-023-04705-3. View

16.

Miao H, Wang N, Shi L, Wang Z, Song W . Overexpression of mircoRNA-137 inhibits cervical cancer cell invasion, migration and epithelial-mesenchymal transition by suppressing the TGF-β/smad pathway via binding to GREM1. Cancer Cell Int. 2019; 19:147. PMC: 6533679. DOI: 10.1186/s12935-019-0852-8. View

17.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View

18.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

19.

Sun J, Zhao J, Jiang F, Wang L, Xiao Q, Han F . Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 2023; 15(1):75. PMC: 10508028. DOI: 10.1186/s13073-023-01229-9. View

20.

Ren J, Smid M, Iaria J, Salvatori D, van Dam H, Zhu H . Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Res. 2019; 21(1):109. PMC: 6751614. DOI: 10.1186/s13058-019-1194-0. View